# Lyric Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lyric-pharmaceuticals

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.lyricpharma.com
- Total disclosed funding: $40M
- Latest round: Series A (Apr 21, 2017)
- Investors on record: 4

## About

Established in 2013 and based in California, US, Lyric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel gastrointestinal therapeutics including LP101 (ulimorelin). In April 2017, Lyric Pharmaceuticals Inc. raised USD 18.97 million in Series A venture funding from Aperture Venture Partners, RiverVest Ventures, Santé Ventures, and Third Point Ventures.

## Funding rounds

- Series A, Apr 21, 2017, $19M — RiverVest Ventures Partners, Aperture Venture Partners, Third Point, Sante Ventures
- Series A, Feb 11, 2015, $20M — RiverVest Ventures Partners, Aperture Venture Partners, Third Point, Sante Ventures
- Seed, Jun 1, 2014, $0.8M — RiverVest Ventures Partners

## Investors

- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Seed, Series A
- Aperture Venture Partners (https://capitalatlas.ai/funds/aperture-venture-partners) — Series A
- Third Point (https://capitalatlas.ai/funds/third-point) — Series A
- Sante Ventures (https://capitalatlas.ai/funds/sante-ventures) — Series A